Factors Associated With Sub - Targeted Therapeutic Dose Of Renin - Angiotensin Blockage Among Chronic Heart Failure With Reduced Ejection Fraction Patients - Trial NCT06382571
Access comprehensive clinical trial information for NCT06382571 through Pure Global AI's free database. This phase not specified trial is sponsored by Chulalongkorn University and is currently Completed. The study focuses on Heart Failure With Reduced Ejection Fraction. Target enrollment is 396 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chulalongkorn University
Timeline & Enrollment
N/A
Jan 01, 2016
Dec 31, 2021
Primary Outcome
factors associated with sub - target dose of ACEIs,ARBs,ARNI
Summary
Objective: To analyze factors associated with Thai heart failure with reduced ejection
 fraction patients who received sub-target doses of Angiotensin converting enzyme inhibitors
 (ACEIs), angiotensin receptor-neprilysin inhibitors (ARNIs), and angiotensin receptor
 blockers (ARBs).
 
 Methods: The retrospective cohort study was designed to collect data on Thai heart failure
 with reduced ejection fraction patients at Out-patient Clinic, Trat Hospital and Phrapokklao
 Hospital from January 2016 to December 2020. Thirteen factors were analyzed to determine
 their association with the sub-target group.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06382571
Non-Device Trial